FibroBiologics Files Patent Application Covering Fibroblast-based Technology for the Potential Treatment of Lupus
FibroBiologics, Inc. (FBLG)
Company Research
Source: GlobeNewswire
HOUSTON, March 28, 2024 (GLOBE NEWSWIRE) -- FibroBiologics (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced the filing of a patent application with the United States Patent Office covering the use of FibroBiologics’ fibroblast cell-based technology for the potential treatment of Lupus. “Our scientists continue to explore clinical opportunities to treat chronic diseases using fibroblast cells, which are natural immune modulators. Successfully leveraging fibroblasts to achieve a durable immune modulation may serve as a potential treatment for Lupus, a debilitating autoimmune disease,” noted Founder & CEO of FibroBiologics, Pete O’Heeron. “The immune modulation capacity of fibroblasts shows early promise in effectively regulating the expansion of pathogenic immune cells and
Show less
Read more
Impact Snapshot
Event Time:
FBLG
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
FBLG alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
FBLG alerts
High impacting FibroBiologics, Inc. news events
Weekly update
A roundup of the hottest topics
FBLG
News
- FibroBiologics to Present at the BIO International Convention 2024GlobeNewswire
- FibroBiologics Plans to Collaborate with Charles River to Manufacture Fibroblast-based Spheroids [Yahoo! Finance]Yahoo! Finance
- FibroBiologics Plans to Collaborate with Charles River to Manufacture Fibroblast-based SpheroidsGlobeNewswire
- FibroBiologics Granted Patent for Regeneration of Cartilage-Type Cells by the Australian Patent OfficeGlobeNewswire
- FibroBiologics Presents Data from Dermal Fibroblast Spheroid-based Treatment of Chronic Wounds in a Diabetes Mouse Model at Advanced Wound Care Summit USAGlobeNewswire
FBLG
Sec Filings
- 4/26/24 - Form 8-K
- 4/26/24 - Form S-1
- 3/29/24 - Form EFFECT
- FBLG's page on the SEC website